Skip to main content
Norris Cotton Cancer Center
In This Section

New Clinical Trials for March 2015

Konstantin Dragnev, Cancer Mechanism
Alliance – NCI Cooperative Group
Olanzapine for the prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in patients receiving Highly Emetogenic Chemotherapy (HEC): A randomized, double-blind, placebo-controlled trial

Merck and Company
A randomized open-label Phase III trial of MK-3475 versus platinum based chemotherapy in 1L subjects with PD-L1 strong metastatic non-small cell lung cancer

Bayer HealthCare Pharmaceuticals, Inc.
Randomized Phase II double blind study of adjuvant regorafenib vs placebo in patients with node positive esophageal cancer that completed pre-operative therapy

Frederick Lansigan, Molecular Therapeutics
PI/Dept Funding
Social media usage within the cancer community of Northern New England

Gary Schwartz, Molecular Therapeutics
A randomized Phase III trial evaluating pathologic complete response rates in patients with hormone receptor-positive, HER2-positive, large operable and locally advanced breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without estrogen deprivation